Compare MIRM & PATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | PATH |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.3B |
| IPO Year | 2019 | 2021 |
| Metric | MIRM | PATH |
|---|---|---|
| Price | $92.00 | $12.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 20 |
| Target Price | ★ $157.71 | $15.41 |
| AVG Volume (30 Days) | 548.2K | ★ 22.4M |
| Earning Date | 11-03-2026 | 12-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.59 | ★ 500.00 |
| EPS | N/A | ★ 0.11 |
| Revenue | $19,138,000.00 | ★ $1,610,572,000.00 |
| Revenue This Year | $37.65 | $11.28 |
| Revenue Next Year | $21.04 | $8.25 |
| P/E Ratio | ★ N/A | $119.55 |
| Revenue Growth | N/A | ★ 12.65 |
| 52 Week Low | $63.23 | $9.20 |
| 52 Week High | $130.00 | $19.84 |
| Indicator | MIRM | PATH |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 39.17 |
| Support Level | $87.38 | $10.58 |
| Resistance Level | $98.34 | $13.33 |
| Average True Range (ATR) | 4.20 | 0.49 |
| MACD | 0.35 | -0.05 |
| Stochastic Oscillator | 48.74 | 8.92 |
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies, including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries, including claims processing, employee onboarding, invoice-to-cash, loan applications, and customer service. The company works in the Americas, Europe, the Middle East, and Africa, and Asia-Pacific, with the maximum revenue from the America.